A Safety Study of 2 Formulations of GlaxoSmithKline Biologicals' (GSK's) Human Rotavirus (HRV) Vaccine in Healthy Infants of Age 6-12 Weeks

Condition:   Infections, Rotavirus Interventions:   Biological: HRV Liquid;   Biological: HRV Lyophilized Sponsor:   GlaxoSmithKline Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials